Chinese COVID-19 vaccines “don’t have very high protection rates”, according to the Chinese CDC Director.
Chinese Center for Disease Control and Prevention (CDC) Director Gao Fu said that Chinese COVID-19 vaccines “don’t have very high protection rates”.
OneNews reported that in a rare admission of the weakness of Chinese COVID-19 vaccines, China’s top disease control official said that their effectiveness was low and the Chinese government was considering mixing them in order to get a boost.
Chinese Centers for Disease Control and Prevention (CDC) Director Gao Fu on Saturday said at a conference in the southwestern city of Chengdu that Chinese COVID-19 vaccines “don’t have very high protection rates”, adding that it’s under formal consideration whether they should use different COVID-19 vaccines from different technical lines for the vaccination process.
Beijing had distributed hundreds of millions of COVID-19 vaccine doses abroad while trying to promote doubt about the effectiveness of the COVID-19 vaccine made by BioNTech SE and Pfizer Inc. using the previously experimental messenger RNA (mRNA) process.
Officials at a news conference on Sunday didn’t respond directly to questions about Gao Fu’s comment or possible changes in official plans. However, another CDC official said that developers were working on mRNA-based COVID-19 vaccines.
READ ALSO: DOH On Roque Hospitalization: “We have our protocols”
Based on a report on OneNews, experts said that mixing COVID-19 vaccines, or sequential vaccination, might boost effectiveness.
Researchers in the United Kingdom were studying a possible combination of Pfizer-BioNTech COVID-19 vaccine and the traditional AstraZeneca-Oxford COVID-19 vaccine.
The coronavirus pandemic, which started in central China in late 2019, marked the first time the Chinese drug industry had played a role in responding to a global health emergency.
According to the foreign ministry, COVID-19 vaccines made by Sinopharm and Sinovac Biotech had been exported to 22 countries — including the Philippines, Mexico, Turkey, Indonesia, Hungary, Brazil, and Turkey.
The effectiveness of a Sinovac COVID-19 vaccine at preventing symptomatic coronavirus infections was found to be as low as 50.4% by researchers in Brazil. By comparison, the Pfizer-BioNTech COVID-19 vaccine had been found to be 97% effective.
Health experts said that Chinese COVID-19 vaccines were unlikely to be sold to the United States, Japan, and Western Europe because of the complexity of the approval process.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.
